https://orcid.org/0000-0001-5537-6767
References
- Peppercorn J . Financial toxicity and societal costs of cancer care: distinct problems require distinct solutions. Oncologist.22(2), 123–125 (2017).
- Danish Medicines Council . About us. (2020). https://medicinraadet.dk/om-os/in-english
- Zafar SY , NewcomerLN, McCarthyJet al. How should we intervene on the financial toxicity of cancer care? One shot, four perspectives. Am. Soc. Clin. Oncol. Educ. B. (37), 35–39 (2018).
- Drummond MF , SchulpherMJ, ClaxtonKet al. Methods for the Economic Evaluation of Health Care Programmes (4th Edition). Oxford University Press, Oxford, UK (2015).
- Ehlers LH , VestergaardAS. Costing in health economic evaluation (1st Ed). Aalborg University Press, Aalborg, Denmark.
- Felber G , ChenC-C, WillsonJet al. US cost burden of relapsed refractory multiple myeloma during third and later lines of treatment. Blood.134(Suppl. 1), 4725–4725 (2019).
- Hannig LH , NielsenLK, IbsenRet al. The impact of changed treatment patterns in multiple myeloma on health-economic cost, myeloma complications and survival; a population based comparison between two time periods in Denmark. Presented at: European Hematology Association 25th Virtual Conference (2020).
- Bødker JS , SønderkærM, VesteghemCet al. Development of a precision medicine workflow in hematological cancers, Aalborg University Hospital, Denmark. Cancers (Basel).12(2), 312 (2020).
- Harris PA , TaylorR, ThielkeRet al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform.42(2), 377–381 (2009).
- Harris PA , TaylorR, MinorBLet al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform.95, 103208 (2019).
- Charlson ME , PompeiP, AlesKL, MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis.40(5), 373–383 (1987).
- MD+CALC . Charlson Comorbidity Index (CCI). (2020). www.mdcalc.com/charlson-comorbidity-index-cci#creator-insights
- Statistics Denmark . Consumer price index. (2020). https://www.dst.dk/en/Statistik/emner/priser-og-forbrug/forbrugerpriser
- Berlingske Media . Valutakurser.dk. (2020). www.valutakurser.dk/
- DRG og Finansiering . Takstsystem 2019. https://sundhedsdatastyrelsen.dk/da/afregning-og-finansiering/takster-drg/takster-2019
- Bang H , TsiatisAA. Estimating medical costs with censored data. Biometrika.87(2), 329–343 (2000).
- Børty L , BrøndumR, BøgstedM. ccostr: an R package for estimating mean costs with censored data. J. Open Source Softw.4(41), 1593 (2019).
- Therneau TM . A package for survival analysis in R. (2020).
- R Core Team . R: A Language and Environment for Statistical Computing [Internet]. (2020). www.r-project.org/
- Danckert B , FerlayJ, EngholmGet al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 8.2. Assoc. Nord. Cancer Regist. Danish Cancer Soc. (2019). www.ancr.nu
- Engholm G , FerlayJ, ChristensenNet al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. (Madr).49(5), 725–736 (2010).
- Sundhedsdatastyrelsen . Indberetning til Sygehusmedicinregisteret. (2019). https://sundhedsdatastyrelsen.dk/da/rammer-og-retningslinjer/sygehusmedicinregisteret
- European Medicines Agency . Lenalidomide Mylan. (2021). www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-mylan
- European Medicines Agency . Bortezomib Fresenius Kabi [Internet]. (2021). www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-fresenius-kabi
- Gonzalez-McQuire S , YongK, LeleuHet al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J. Med. Econ.21(5), 450–467 (2018).
- Tran D , KamalakarR, ManthenaS, KarveS. Economic burden of multiple myeloma: results from a large employer-sponsored real-world administrative claims database, 2012 to 2018. Blood.134(Suppl. 1), 3414–3414 (2019).
- Gulla A , AndersonKC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica.105(10), 2358–2367 (2020).